Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Biomira initiates next stage of phase II testing of BLP25/liposomal IL-2

Jan. 26, 2000

Neurocrine Biosciences updates clinical progress with IL-4 fusion toxin

Jan. 21, 2000

Avax Technologies' O-Vax IND accepted

Jan. 19, 2000

Oxford BioMedica acquires novel antibody technology

Jan. 17, 2000

AltaRex in-licenses antibody from NIH for AIT platform

Jan. 14, 2000

Ligand sells Marathon assets to CoPharma

Jan. 14, 2000

Japanese marketing approval no longer sought for Mochida's TNF

Jan. 12, 2000

FDA grants priority review status to Wyeth-Ayerst's therapy for relapsed adult AML

Jan. 11, 2000

New developments announced for AltaRex's ovarian cancer therapy

Jan. 6, 2000

Maxamine granted orphan drug status for AML

Jan. 5, 2000

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...